

MAY 19 2005

**9. 510(K) SUMMARY**

**Submitted By:** Mark Bleyer, President  
Cook Biotech Incorporated  
1425 Innovation Place  
West Lafayette, IN 47906  
(765) 497-3355  
May 6, 2005

**Names of Device:**

Trade Name: SIS Facial Implant  
Common/Usual Name: Surgical Mesh  
Proposed classification name: Surgical Mesh  
21 CFR 878.3300 (FTM)  
Class II

**Intended Use:**

The SIS Facial Implant is intended for use to provide soft tissue repair or reinforcement in plastic and reconstructive surgery of the face and head. The device is supplied sterile and is intended for one-time use.

**Predicate Devices:**

The SIS Facial Implant is similar to predicate devices, including the SIS Plastic Surgery Matrix (K034039) and SURGISIS® Soft Tissue Graft (K980431) manufactured by Cook Biotech Incorporated, Permacol (K013625) manufactured by Tissue Science Laboratories, PLC, and Advanta PTFE Facial Implant (K992991) manufactured by Atrium Medical Corporation.

**Device Description:**

The SIS Facial Implant is manufactured from porcine small intestinal submucosa (SIS) and is nominally supplied in a strand configuration pre-attached to a trocar. The device is packaged in a lyophilized (dried) state, and supplied sterile in a sealed double pouch system.

**Substantial Equivalence:**

The SIS Facial Implant is similar with respect to intended use, materials and technological characteristics to the above predicate devices in terms of 510(k) substantial equivalence as shown through bench and biocompatibility testing.

**Discussion of Tests and Test Results:**

The material comprising the SIS Facial Implant was subjected to extensive biocompatibility testing, viral inactivation testing, and mechanical testing. Outcomes show the device to be biocompatible, manufacturing processes to adequately disinfect the material, and mechanical characteristics to be sufficient.

**Conclusions Drawn from the Tests:**

Outcomes from the evaluation of the SIS Facial Implant provide evidence of its suitability for use in soft tissue reconstruction and substantial equivalency to predicate devices in terms of intended use and technological characteristics.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAY 19 2005

Mr. Mark Bleyer  
President  
Cook Biotech Incorporated  
1425 Innovation Place  
West Lafayette, Indiana 47906

Re: K050246

Trade/Device Name: SIS Facial Implant  
Regulation Number: 21 CFR 878.3300  
Regulation Name: Surgical mesh  
Regulatory Class: II  
Product Code: FTM  
Dated: May 6, 2005  
Received: May 9, 2005

Dear Mr. Bleyer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. Mark Bleyer

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115 . Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Miriam C. Provost, Ph.D.  
Acting Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K050246  
Device Name: SIS Facial Implant

### Indications for Use:

**The SIS Facial Implant is intended for use to provide soft tissue repair or reinforcement in plastic and reconstructive surgery of the face and head. The device is supplied sterile and is intended for one-time use.**

Prescription Use X AND/OR Over-The-Counter Use \_\_\_\_\_  
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1

  
Michael J. Sciarola, M.D.  
Associate Director  
Office of Devices and Radiological Health  
U.S. Food and Drug Administration  
K050246